Medarex and Lonza Sign Collaboration Agreement for the Supply of Antibody-Based Products

Agreement Includes Manufacture of Antibodies and Antibody Drug Conjugates

10-Jul-2009 - Lonza and Medarex, Inc. announced that they have signed an agreement giving Medarex the option to work with Lonza as a collaboration partner to provide manufacturing services in support of the development and commercialization of Medarex’s pipeline of therapeutic proteins and antibody drug ...

Oxford Genome Sciences announces new Therapeutic Antibody Deal with Medarex

New agreement to drive the development of OGeS' own pipeline of antibodies in cancer

20-Sep-2007 - Oxford Genome Sciences (UK) Ltd (OGeS) announced a second partnering agreement with Medarex, Inc. This new agreement provides OGeS with broad access to Medarex's fully human antibody technology and will potentially enable OGeS to accelerate the development of its own pipeline of novel fully human ...

Medarex and Compugen Announce Therapeutic Antibody Co-Development Agreement

25-Jan-2007 - Medarex, Inc. and Compugen Ltd. have entered into a collaborative agreement to develop novel monoclonal antibody-based therapeutics for oncology and autoimmune diseases. Under the terms of the agreement, Medarex and Compugen plan to share discovery, development and commercialization ...

BioWa and Medarex Announce Allowance of Investigational New Drug Application for Second-Generation Anti-CD30 Antibody (MDX-1401)

16-Jan-2007 - BioWa, Inc. and Medarex, Inc. announced the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1401, a fully human antibody that targets CD30-positive lymphomas. MDX-1401 is enhanced for greater Fc receptor mediated antibody ...

Medarex and GenPat77 Announce Therapeutic Antibody Co-Development Agreement

24-Aug-2006 - Medarex, Inc. and GenPat77 Pharmacogenetics AG have entered into a collaborative agreement to develop fully human therapeutic antibody products. The companies plan to use Medarex's UltiMAb Human Antibody Development System® to generate antibodies to novel disease targets provided by ...

Celera Genomics and Medarex Establish Therapeutic Antibody Collaboration in Cancer

Collaboration Combines Celera's Protein Discoveries with Medarex's Expertise in Developing Fully Human Antibody Therapeutics

26-Jun-2006 - Celera Genomics, an Applera Corporation business, and Medarex, Inc. formed a strategic collaboration to discover and develop fully human antibodies for the potential treatment of multiple cancer indications. The collaboration will encompass the development of therapeutic antibodies against ...

Oxford Genome Sciences and Medarex Sign Therapeutic Antibody Collaboration Agreement in Cancer

12-May-2006 - Oxford Genome Sciences (UK) Ltd and Medarex, Inc. announced that they have entered into a strategic collaboration to discover and develop new human antibody therapeutics for the treatment of cancers, including colorectal cancer. The collaboration combines OGeS' ability to discover novel targets ...

Ono and Medarex Enter Into Second Collaboration for the Development of a Fully Human Antibody Therapeutic

30-Mar-2006 - Ono Pharmaceutical Co., Ltd. and Medarex, Inc. announced that they have entered into a collaborative agreement to research and develop a fully human anti-SDF-1 antibody for the potential treatment of multiple indications. This is the second antibody development collaboration between Ono and ...

Organon and Medarex announce antibody development agreement

03-Feb-2006 - Organon and Medarex, Inc. announced an agreement for the development of therapeutic antibodies. Organon intends to use Medarex's UltiMAb Human Antibody Development System®, which allows for the discovery of fully human antibodies in mice, to generate therapeutic antibodies against a variety of ...

Genmab acquieres worldwide rights for HUMAX-CD4

05-Jul-2005 - Genmab A/S announced that it has licensed from Medarex, Inc. the European and Asian rights to utilize Medarex's UltiMAb® technology to develop and commercialize antibodies raised against the CD4 antigen, including HuMax-CD4(TM), a fully human antibody that Genmab currently has in Phase III ...